全文获取类型
收费全文 | 350篇 |
免费 | 16篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 1篇 |
妇产科学 | 14篇 |
基础医学 | 49篇 |
口腔科学 | 1篇 |
临床医学 | 20篇 |
内科学 | 73篇 |
皮肤病学 | 1篇 |
神经病学 | 25篇 |
特种医学 | 5篇 |
外科学 | 54篇 |
预防医学 | 9篇 |
眼科学 | 1篇 |
药学 | 36篇 |
肿瘤学 | 74篇 |
出版年
2024年 | 1篇 |
2023年 | 3篇 |
2022年 | 7篇 |
2021年 | 10篇 |
2020年 | 10篇 |
2019年 | 10篇 |
2018年 | 7篇 |
2017年 | 8篇 |
2016年 | 19篇 |
2015年 | 10篇 |
2014年 | 12篇 |
2013年 | 17篇 |
2012年 | 25篇 |
2011年 | 16篇 |
2010年 | 16篇 |
2009年 | 18篇 |
2008年 | 15篇 |
2007年 | 14篇 |
2006年 | 17篇 |
2005年 | 11篇 |
2004年 | 24篇 |
2003年 | 15篇 |
2002年 | 19篇 |
2001年 | 11篇 |
2000年 | 15篇 |
1999年 | 4篇 |
1998年 | 4篇 |
1997年 | 3篇 |
1996年 | 1篇 |
1994年 | 6篇 |
1992年 | 9篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1979年 | 1篇 |
排序方式: 共有366条查询结果,搜索用时 0 毫秒
1.
S Plescia G Daidone D Raffa M L Bajardi A Caruso V Cutuli M Amico-Roxas 《Il Farmaco; edizione pratica》1992,47(4):465-475
A number of new 3-(isoxazol-5-yl)-quinazolin-4(3H)-ones was prepared and tested, together a few analogues previously obtained, for their analgesic, antipyretic and antiinflammatory activities, as well as for their acute toxicity and ulcerogenic effects. In the carrageenan rat foot edema model one of the tested compounds showed activity and LD50 comparable to that of ASA, but the ulceration index approximated zero value. 相似文献
2.
Serum Interferon (IFN)-Neutralizing Antibodies and Bioactivities of IFNs in Patients with Severe Type II Essential Mixed Cryoglobulinemia 下载免费PDF全文
Carolina Scagnolari Milvia Casato Francesca Bellomi Francesca De Pisa Ombretta Turriziani Rossella Coviello Maria Rosaria Pirro Ferdinando Dianzani Guido Antonelli 《Clinical and Vaccine Immunology : CVI》2003,10(1):70-77
The efficacy of alpha interferon (IFN-α) in the treatment of severe type II essential mixed cryoglobulinemia (EMC) has been reported previously. In some patients, the development of neutralizing antibodies to recombinant IFN-α (rIFN-α) can affect the clinical response achieved with rIFN-α; a second treatment with natural IFN-α preparations may reinduce the clinical response. In the present study the ability of leukocyte IFN (LeIFN) to restore the response was investigated from a pharmacodynamic viewpoint. Specifically, the pharmacodynamic profiles of different IFN-α preparations were studied by measuring the serum neopterin levels and the levels of expression of protein MxA mRNA in in vivo peripheral blood mononuclear cells in two patients with EMC whose resistance to rIFN-α2a treatment increased concomitantly with the development of neutralizing antibodies. These markers were measured before injection and at 24 and 48 h after a single injection of rIFN-α2a, consensus IFN [(C)IFN], or LeIFN. No increase or only a slight increase in MxA mRNA levels was detectable after administration of rIFN-α2a or (C)IFN, whereas a significant increase (≥10-fold) in MxA mRNA expression was recorded following administration of LeIFN. The neutralizing antibodies to rIFN-α2a cross-react with (C)IFN. Sera from these patients neutralized most but not all of the subtypes present in the natural IFN-α (LeIFN) mixture, and no significant increase in neopterin levels was observed after these patients were switched to LeIFN treatment. In summary, the data demonstrate that the problem of neutralizing antibodies still exists and that LeIFN may induce an increase in the level of MxA mRNA expression but not an increase in neopterin levels in patients who are resistant to treatment with rIFN-α2a or (C)IFN. 相似文献
3.
Carolina Scagnolari Francesca Bellomi Ombretta Turriziani Francesca Bagnato Valentina Tomassini Vito Lavolpe Marilena Ruggieri Fabrizio Bruschi Giuseppe Meucci Giordano Dicuonzo Guido Antonelli 《Journal of interferon & cytokine research》2002,22(2):207-213
The frequencies of anti-interferon-beta (IFN-beta) antibody development reported to date in patients treated with different IFN-beta preparations are not readily comparable mainly because of differences in underlying diseases and assay methods. Thus, the frequency of neutralizing antibody (NAb) and binding antibody (BAb) development was analyzed in a sample of sera derived from a homogeneous group of relapsing-remitting multiple sclerosis (RRMS) patients treated with different IFN-beta preparations. The frequency of developing NAb and BAb to IFN-beta varied according to the IFN-beta given. Specifically, the NAb seroconversion frequency was significantly higher in patients treated with Betaferon, Schering AG, Berlin, Germany (31.3%) than in patients treated with both preparations of recombinant IFN-beta 1a (Rebif, Serono, Geneva, Switzerland [7.4%] or Avonex, Biogen, Cambridge, MA [6.3%]). Analysis of BAb seroconversion frequency in the same patients revealed that different IFN-beta preparations may also have different capability to induce BAb development and that BAb are produced during IFN-beta therapy at a significantly higher rate than NAb. Our main conclusion is that different human IFN-beta preparations may possess different immunogenicities, leading to varying frequency of development of antibody to IFN-beta in RRMS. 相似文献
4.
Ernesto Falcidia Agata Grillo Piero Pavone Nunzio Cutuli Haruo Takabayashi Rosario R. Trifiletti Conrad T. Gilliam 《American journal of medical genetics. Part A》2001,101(3):262-267
The isolation and analysis of nucleated fetal cells (NFCs) from maternal blood may represent a new approach to noninvasive prenatal diagnosis. Although promising, these techniques require highly accurate separation of NFCs from nucleated cells of maternal origin; the two major problems limiting these techniques are the relative rarity of fetal cells in maternal blood and the need to establish their fetal origin. We now report a novel procedure that has allowed accurate separation of NFCs from maternal cells. The technique reported involves direct micromanipulator isolation of histochemically identified hemoglobin F‐positive nucleated cells to obtain fetal nucleated red blood cells (FNRBCs) of high yield and purity. Using this technique, followed by cell‐by‐cell multicolor fluorescence in situ hybridization (FISH) analysis of purified FNRBCs, we were able to detect some of the most common human aneuploidies (including Down syndrome, Klinefelter syndrome, and trisomy 13) in 33 pregnant women referred for amniocentesis. The procedure used, which can be completed in <72 hrs, produced complete concordance with the results of amniocentesis. We also confirm findings of prior studies suggesting that the number of FNRBCs in maternal circulation is remarkably higher in abnormal pregnancies than in normal pregnancies, especially in women carrying a fetus with trisomy 21. © 2001 Wiley‐Liss, Inc. 相似文献
5.
Luca Degli Esposti Valentina Perrone Diego Sangiorgi Margherita Andretta Fausto Bartolini Arturo Cavaliere Andrea Ciaccia Stefania Dell'orco Stefano Grego Sara Salzano Loredana Ubertazzo Adriano Vercellone Davide Gatti Angelo Fassio Ombretta Viapiana Maurizio Rossini Giovanni Adami 《Journal of bone and mineral research》2021,36(11):2177-2183
The determinants of the susceptibility to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection and severe coronavirus disease 2019 (COVID-19) manifestations are yet not fully understood. Amino-bisphosphonates (N-BPs) have anti-inflammatory properties and have been shown to reduce the incidence of lower respiratory infections, cardiovascular events, and cancer. We conducted a population-based retrospective observational cohort study with the primary objective of determining if oral N-BPs treatment can play a role in the susceptibility to development of severe COVID-19. Administrative International Classification of Diseases, Ninth Revision, Clinical ModificationI (ICD-9-CM) and anatomical-therapeutic chemical (ATC) code data, representative of Italian population (9% sample of the overall population), were analyzed. Oral N-BPs (mainly alendronate and risedronate) were included in the analysis, zoledronic acid was excluded because of the low number of patients at risk. Incidence of COVID-19 hospitalization was 12.32 (95% confidence interval [CI], 9.61–15.04) and 11.55 (95% CI, 8.91–14.20), of intensive care unit (ICU) utilization because of COVID-19 was 1.25 (95% CI, 0.38–2.11) and 1.42 (95% CI, 0.49–2.36), and of all-cause death was 4.06 (95% CI, 2.50–5.61) and 3.96 (95% CI, 2.41–5.51) for oral N-BPs users and nonusers, respectively. Sensitivity analyses that excluded patients with prevalent vertebral or hip fragility fractures and without concomitant glucocorticoid treatment yielded similar results. In conclusion, we found that the incidence of COVID-19 hospitalization, intensive care unit (ICU) utilization, and COVID-19 potentially related mortality were similar in N-BPs–treated and nontreated subjects. Similar results were found in N-BPs versus other anti-osteoporotic drugs. We provide real-life data on the safety of oral N-BPs in terms of severe COVID-19 risk on a population-based cohort. Our results do not support the hypothesis that oral N-BPs can prevent COVID-19 infection and/or severe COVID-19; however, they do not seem to increase the risk. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). 相似文献
6.
The authors report on 2 cases of uterine dissemination from primary breast carcinoma. Special emphasis is made on this atypical site of metastases and on the necessity of a gynecological work-up in patients previously treated for breast cancer. 相似文献
7.
Prevalence and Factors Associated with Subclinical Left Ventricular Systolic Dysfunction Evaluated by Mid‐Wall Mechanics in Rheumatoid Arthritis 下载免费PDF全文
8.
9.
10.
Bixio Riccardo Bertelle Davide Pistillo Francesca Pedrollo Elisa Carletto Antonio Rossini Maurizio Viapiana Ombretta 《Clinical rheumatology》2022,41(4):1247-1254
Clinical Rheumatology - Myasthenia gravis is an autoimmune disease affecting the neuromuscular junction, often associated with other autoimmune diseases, including rheumatoid arthritis. Patients... 相似文献